Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
0(0%)
Results Posted
70%(7 trials)
Terminated
2(14%)

Phase Distribution

Ph phase_3
5
36%
Ph phase_1
2
14%
Ph early_phase_1
1
7%
Ph phase_2
2
14%
Ph phase_4
4
29%

Phase Distribution

3

Early Stage

2

Mid Stage

9

Late Stage

Phase Distribution14 total trials
Early Phase 1First-in-human
1(7.1%)
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
2(14.3%)
Phase 3Large-scale testing
5(35.7%)
Phase 4Post-market surveillance
4(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.9%

10 of 13 finished

Non-Completion Rate

23.1%

3 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(10)
Terminated(3)
Other(1)

Detailed Status

Completed10
Terminated2
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (7.1%)
Phase 12 (14.3%)
Phase 22 (14.3%)
Phase 35 (35.7%)
Phase 44 (28.6%)

Trials by Status

withdrawn17%
unknown17%
completed1071%
terminated214%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT05270863Phase 3

Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia

Completed
NCT03785340Phase 3

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

Completed
NCT03591874Phase 3

Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

Terminated
NCT03760185Phase 2

Pupil Dilation for Treatment of IFIS

Completed
NCT05001243Phase 1

Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients

Unknown
NCT03323164Phase 4

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study

Completed
NCT03497442Early Phase 1

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

Completed
NCT01959230Phase 3

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

Completed
NCT01959243Phase 3

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

Completed
NCT03966560Phase 4

Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma

Completed
NCT03173365Phase 2

The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients

Terminated
NCT02039765Phase 1

Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.

Completed
NCT02856919Phase 4

A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema.

Completed
NCT02568111Phase 4

Brimonidine Tartrate for the Treatment of Injection Related Erythema

Withdrawn

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14